Chemomab Therapeutics Ltd (CMMB)
0.8600
+0.12
(+16.22%)
USD |
NASDAQ |
May 06, 16:00
0.8602
0.00 (0.00%)
After-Hours: 20:00
Chemomab Therapeutics Cash from Financing (TTM): 0.538M for June 30, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
June 30, 2023 | 0.538M |
March 31, 2023 | -0.808M |
December 31, 2022 | -0.808M |
September 30, 2022 | -0.02M |
June 30, 2022 | -0.131M |
March 31, 2022 | 13.28M |
Date | Value |
---|---|
December 31, 2021 | 61.07M |
September 30, 2021 | 61.72M |
June 30, 2021 | 62.35M |
March 31, 2021 | 52.05M |
December 31, 2020 | 4.75M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-0.808M
Minimum
Dec 2022
62.35M
Maximum
Jun 2021
23.09M
Average
4.75M
Median
Dec 2020
Cash from Financing (TTM) Benchmarks
Compugen Ltd | -- |
Pluri Inc | -- |
BioLine Rx Ltd | 15.06M |
Can Fite Biofarma Ltd | -- |
BiomX Inc | 2.899M |